Alnylam Pharmaceuticals stock
Price history
−63.65% over the period1 year: from $453.97 (November 13, 2025) to $165.04 (November 13, 2026), −63.65%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $165.04 |
| October 30, 2026 | $165.00 |
| September 30, 2026 | $246.74 |
| August 31, 2026 | $240.69 |
| July 31, 2026 | $205.52 |
| June 30, 2026 | $301.03 |
| May 29, 2026 | $301.98 |
| April 30, 2026 | $309.49 |
| March 31, 2026 | $330.87 |
| February 27, 2026 | $332.92 |
| January 30, 2026 | $338.06 |
| December 31, 2025 | $397.65 |
| November 28, 2025 | $451.23 |
| November 13, 2025 | $453.97 |
At a glance
The company
Discovers, develops, manufactures and commercializes RNA interference-based therapeutics for rare and common diseases
Latest results
Quarter to September 30, 2026 · EPS $16.26 (estimate $1.74)
TickerLandia's take on Alnylam Pharmaceuticals
- Cheaper than similar companies: trailing 12-month P/E 8.3 vs 33 (−75%) in a group of 6.
- Strong point: Profitability (73/100 in its group). Weak point: Market momentum (4/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−65.60% from the 52-week high
Analysts · 30 analysts
Average target$299.96+81.75% vs. price
Buy 21 · Hold 9 · Sell 0 · Buy
TickerLandia Fingerprint: Alnylam Pharmaceuticals
Compared with similar companies: very weak momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow30
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 15.2 23 P/E (trailing 12 months) 8.34 12 EV/EBITDA 20.8 41 Price/book 6.13 54 Price/sales 4.41 20 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 77.3% 57 Operating margin 19.5% 48 Net margin 52.8% 89 ROE 138.1% 97 ROA 9.5% 74 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 43.3% 47 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthhigh70
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +52.98% 71 Revenue growth (year over year) +16.70% 41 Earnings growth (year over year) +633.50% 99 Financial strengthlow23
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.35 12 Interest coverage 1.99 34 Debt/equitycounts in reverse: lower means more financial strength 0.83 11 Current ratio 2.48 35 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak4
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −63.65% 0 Distance from 200-day average −40.09% 1 Relative strength (3 months) −21.77% 10 Relative strength (6 months) −40.49% 4 Riskhigh72
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 68.0% 99 Volatility (60 days) 73.4% 92 Beta (1 year) 0.18 26
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Alnylam Pharmaceuticals is cheaper than similar companies
Alnylam Pharmaceuticals's P/E (trailing 12 months): 8.34, −75% against the median of a group of 6 similar companies (33.0).
Compared with 6 similar companies
| Metric | Alnylam Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 8.34 | Low | |
| Forward P/E | 15.2 | Middle | |
| Operating margin | 19.5% | Middle | |
| ROE | 138.1% | High | |
| Debt/equity | 0.83 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Alnylam Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.29B
Latest quarter · Q2 2026
Net income
$164.49M
Latest quarter · Q2 2026
Quarterly net margin
12.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $22.11B
- P/E
- 8.3
- EPS
- $19.80
- Volume
- 3.59M
- Daily trading
- €520.28M
- Dividend yield
- 0.00%
How Alnylam Pharmaceuticals is changing
All resultsRevenue grew 49.8% a year on average over the last 5 years
Operating margin rose from −75.7% to 13.5%
Shares outstanding up 17.1% in 5 years
Returns
Alnylam Pharmaceuticals returns
$1,000 invested in Alnylam Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $952 today: −4.77% in total, −0.97% per year. This is the price return only: dividends are excluded.
| Period | Alnylam Pharmaceuticals | Nasdaq 100 | $1,000 becomes |
|---|---|---|---|
| 1 month | −26.26% | −8.59% | $737 |
| 6 months | −43.38% | −4.85% | $566 |
| Year to date | −58.50% | +10.67% | $415 |
| 1 year | −63.65% | +11.80% | $364 |
| 3 years | +0.02% | +80.48% | $1,000 |
| 5 years | −4.77% | +72.61% | $952 |
| 10 years | +229.82% | +494.29% | $3,298 |
Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Alnylam Pharmaceuticals: technical analysis
Alnylam Pharmaceuticals is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 66.4% below its all-time closing high ($491.22, October 20, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- −40.09%
Support and resistance
Price areas where Alnylam Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$284.69+72.50%4 touches, last on June 3, 2026
- Resistance$272.59+65.17%2 touches, last on September 8, 2026
- Resistance$235.46+42.67%4 touches, last on October 28, 2026
- Last price$165.04
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved little with the Nasdaq 100.
- Beta (1 year) vs Nasdaq 100
- 0.18
- Volatility (60 sessions, annualised)
- 73.4%
- Largest fall in the last year
- −67.96%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Alnylam Pharmaceuticals: seasonality
Average monthly price change over 23 years
Over the last 23 years, the strongest month for Alnylam Pharmaceuticals has been July: +8.86% on average, positive in 15 years out of 23. The weakest has been October: −5.46% on average, positive in 9 years out of 23. November, the current month, has been positive in 16 years out of 22 (+7.84% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.88% | +0.29% | 11 of 22 |
| February | +0.27% | −1.55% | 10 of 22 |
| March | −1.27% | −0.69% | 10 of 22 |
| April | −2.19% | −1.14% | 8 of 22 |
| May | +3.82% | +2.38% | 13 of 22 |
| June | +6.14% | +2.66% | 14 of 23 |
| July | +8.86% | +3.74% | 15 of 23 |
| August | +4.28% | +2.60% | 14 of 23 |
| September | +3.42% | +2.13% | 13 of 23 |
| October | −5.46% | −8.10% | 9 of 23 |
| November | +7.84% | +6.33% | 16 of 22 |
| December | +0.62% | −1.00% | 10 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Alnylam Pharmaceuticals and its competitors
Alnylam's customers are patients with rare and chronic diseases in the United States, Europe and other international markets, where its RNA interference therapies are sold for conditions such as transthyretin amyloidosis, hypercholesterolemia, hemophilia and primary hyperoxaluria type 1. Its marketed medicines include ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI and OXLUMO, while its pipeline spans cardiovascular, metabolic, liver, neurological and hematological diseases, with several candidates in Phase 3 trials.
- Headquarters
- Cambridge, United States
- Employees
- 2,500
- Founded
- 2002
- Chief executive
- Yvonne Greenstreet
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Alnylam PharmaceuticalsALNY | $22.11B | 19.5% | 8.34 | −43.38% |
| BioNTechBNTX | $21.22B | -55.4% | — | −7.19% |
| IncyteINCY | $24.66B | 32.2% | 61.7 | +22.41% |
| InsmedINSM | $26.58B | -41.7% | — | +2.69% |
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +13.06% |
| Roivant SciencesROIV | $28.64B | -3,226.3% | — | +35.28% |
Same industry or related industries, similar size. Compare Alnylam Pharmaceuticals with its competitors · Full profile
More on Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals revenue and financials
- Alnylam Pharmaceuticals valuation
- Alnylam Pharmaceuticals stock return
- Alnylam Pharmaceuticals employees, headquarters and business
